Turner T, Prowse C V, Prescott R J, Cash J D
Br J Haematol. 1981 Jan;47(1):65-75. doi: 10.1111/j.1365-2141.1981.tb02762.x.
Low birth weight infants, preterm infants with respiratory distress syndrome and mature infants with asphyxia were screened for coagulation abnormalities as soon as possible after birth. Those with abnormal haemostasis were assigned to control or treatment groups and, in the latter case, were given prothrombin complex concentrate, cryoprecipitate or platelet concentrate as appropriate. This treatment was largely successful in correcting haemostatic defects but did not result in any change in mortality. There was no evidence of adverse or beneficial side-effects of treatment.
对低体重儿、患有呼吸窘迫综合征的早产儿以及窒息的足月儿在出生后尽快进行凝血异常筛查。止血功能异常者被分为对照组或治疗组，后者则根据情况给予凝血酶原复合物浓缩剂、冷沉淀或血小板浓缩剂。这种治疗在很大程度上成功纠正了止血缺陷，但并未导致死亡率发生任何变化。没有证据表明治疗存在不良或有益的副作用。
